WO2014145156A3 - Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride - Google Patents

Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride Download PDF

Info

Publication number
WO2014145156A3
WO2014145156A3 PCT/US2014/029872 US2014029872W WO2014145156A3 WO 2014145156 A3 WO2014145156 A3 WO 2014145156A3 US 2014029872 W US2014029872 W US 2014029872W WO 2014145156 A3 WO2014145156 A3 WO 2014145156A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydrochloride
cyclobenzaprine
amitriptyline
eutectic
eutectic formulations
Prior art date
Application number
PCT/US2014/029872
Other languages
French (fr)
Other versions
WO2014145156A2 (en
Inventor
Marino Nebuloni
Patrizia COLOMBO
Original Assignee
Tonix Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2014145156(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US14/776,624 priority Critical patent/US10117936B2/en
Priority to SI201431487T priority patent/SI2968992T1/en
Priority to JP2016503239A priority patent/JP6310542B2/en
Priority to CN201910263541.6A priority patent/CN110152005B/en
Priority to NZ631152A priority patent/NZ631152A/en
Priority to CA2904812A priority patent/CA2904812C/en
Priority to ES14762323T priority patent/ES2769879T3/en
Priority to MX2015012622A priority patent/MX370021B/en
Priority to MYPI2015703142A priority patent/MY196014A/en
Priority to PL14762323T priority patent/PL2968992T3/en
Priority to EP14762323.5A priority patent/EP2968992B8/en
Priority to DK14762323.5T priority patent/DK2968992T3/en
Priority to EP19214535.7A priority patent/EP3650081B1/en
Priority to CN201480024011.1A priority patent/CN105142730B/en
Priority to AU2014233277A priority patent/AU2014233277B2/en
Priority to LTEP14762323.5T priority patent/LT2968992T/en
Priority to RS20200094A priority patent/RS60015B1/en
Priority to SG11201507124XA priority patent/SG11201507124XA/en
Priority to BR112015022095-9A priority patent/BR112015022095B1/en
Application filed by Tonix Pharmaceuticals, Inc. filed Critical Tonix Pharmaceuticals, Inc.
Publication of WO2014145156A2 publication Critical patent/WO2014145156A2/en
Publication of WO2014145156A3 publication Critical patent/WO2014145156A3/en
Priority to IL24135315A priority patent/IL241353B/en
Priority to SA515361124A priority patent/SA515361124B1/en
Priority to HK16106690.2A priority patent/HK1218727A1/en
Priority to US16/140,090 priority patent/US10864175B2/en
Priority to US16/140,105 priority patent/US10864176B2/en
Priority to HRP20200055TT priority patent/HRP20200055T1/en
Priority to CY20201100104T priority patent/CY1122740T1/en
Priority to US17/082,949 priority patent/US11839594B2/en
Priority to US17/121,547 priority patent/US11737991B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Abstract

The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.
PCT/US2014/029872 2013-03-15 2014-03-14 Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride WO2014145156A2 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
SI201431487T SI2968992T1 (en) 2013-03-15 2014-03-14 Eutectic formulations of cyclobenzaprine hydrochloride and mannitol
RS20200094A RS60015B1 (en) 2013-03-15 2014-03-14 Eutectic formulations of cyclobenzaprine hydrochloride and mannitol
AU2014233277A AU2014233277B2 (en) 2013-03-15 2014-03-14 Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
CN201910263541.6A CN110152005B (en) 2013-03-15 2014-03-14 Eutectic formulation of cyclobenzaprine and amitriptyline hydrochloride
NZ631152A NZ631152A (en) 2013-03-15 2014-03-14 Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
CA2904812A CA2904812C (en) 2013-03-15 2014-03-14 Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
ES14762323T ES2769879T3 (en) 2013-03-15 2014-03-14 Eutectic formulations of cyclobenzaprine hydrochloride and mannitol
MX2015012622A MX370021B (en) 2013-03-15 2014-03-14 Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride.
MYPI2015703142A MY196014A (en) 2013-03-15 2014-03-14 Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride
PL14762323T PL2968992T3 (en) 2013-03-15 2014-03-14 Eutectic formulations of cyclobenzaprine hydrochloride and mannitol
EP14762323.5A EP2968992B8 (en) 2013-03-15 2014-03-14 Eutectic formulations of cyclobenzaprine hydrochloride and mannitol
DK14762323.5T DK2968992T3 (en) 2013-03-15 2014-03-14 Eutetic formulations of cyclobenzaprine hydrochloride and mannitol
EP19214535.7A EP3650081B1 (en) 2013-03-15 2014-03-14 Eutectic formulations of cyclobenzaprine hydrochloride and mannitol
CN201480024011.1A CN105142730B (en) 2013-03-15 2014-03-14 The eutectic mixture preparaton of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
JP2016503239A JP6310542B2 (en) 2013-03-15 2014-03-14 Eutectic preparation of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
US14/776,624 US10117936B2 (en) 2013-03-15 2014-03-14 Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
LTEP14762323.5T LT2968992T (en) 2013-03-15 2014-03-14 Eutectic formulations of cyclobenzaprine hydrochloride and mannitol
SG11201507124XA SG11201507124XA (en) 2013-03-15 2014-03-14 Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
BR112015022095-9A BR112015022095B1 (en) 2013-03-15 2014-03-14 PHARMACEUTICAL COMPOSITION, MANUFACTURING METHODS, EUTETIC COMPOSITION AND USE OF COMPOSITIONS
IL24135315A IL241353B (en) 2013-03-15 2015-09-09 Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
SA515361124A SA515361124B1 (en) 2013-03-15 2015-09-14 Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
HK16106690.2A HK1218727A1 (en) 2013-03-15 2016-06-10 Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
US16/140,090 US10864175B2 (en) 2013-03-15 2018-09-24 Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
US16/140,105 US10864176B2 (en) 2013-03-15 2018-09-24 Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
HRP20200055TT HRP20200055T1 (en) 2013-03-15 2020-01-14 Eutectic formulations of cyclobenzaprine hydrochloride and mannitol
CY20201100104T CY1122740T1 (en) 2013-03-15 2020-02-05 CYCLOBenzaprine Hydrochloride and Mannitol Euthetic Formulations
US17/082,949 US11839594B2 (en) 2013-03-15 2020-10-28 Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
US17/121,547 US11737991B2 (en) 2013-03-15 2020-12-14 Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792757P 2013-03-15 2013-03-15
US61/792,757 2013-03-15

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US14/776,624 A-371-Of-International US10117936B2 (en) 2013-03-15 2014-03-14 Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
US16/140,105 Division US10864176B2 (en) 2013-03-15 2018-09-24 Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
US16/140,090 Continuation US10864175B2 (en) 2013-03-15 2018-09-24 Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

Publications (2)

Publication Number Publication Date
WO2014145156A2 WO2014145156A2 (en) 2014-09-18
WO2014145156A3 true WO2014145156A3 (en) 2015-01-08

Family

ID=51538423

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/029872 WO2014145156A2 (en) 2013-03-15 2014-03-14 Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

Country Status (25)

Country Link
US (9) US10117936B2 (en)
EP (2) EP2968992B8 (en)
JP (5) JP6310542B2 (en)
CN (2) CN110152005B (en)
AU (1) AU2014233277B2 (en)
CA (2) CA3119755A1 (en)
CY (1) CY1122740T1 (en)
DK (1) DK2968992T3 (en)
ES (1) ES2769879T3 (en)
HK (1) HK1218727A1 (en)
HR (1) HRP20200055T1 (en)
HU (1) HUE047547T2 (en)
IL (1) IL241353B (en)
LT (1) LT2968992T (en)
MX (2) MX370021B (en)
MY (1) MY196014A (en)
NZ (1) NZ631152A (en)
PL (1) PL2968992T3 (en)
PT (1) PT2968992T (en)
RS (1) RS60015B1 (en)
SA (1) SA515361124B1 (en)
SG (2) SG10201707528WA (en)
SI (1) SI2968992T1 (en)
TW (2) TWI661825B (en)
WO (1) WO2014145156A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2459064A1 (en) 2009-07-27 2012-06-06 Cardiac Pacemakers, Inc. Medical device for treating heart failure through blood volume redistribution
WO2011062614A1 (en) 2009-11-20 2011-05-26 Tonix Pharmaceuticals, Inc. Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
JP6259452B2 (en) * 2012-06-15 2018-01-10 トニックス ファーマシューティカルズ， インコーポレイテッド Compositions and methods for transmucosal absorption
CA3119755A1 (en) 2013-03-15 2014-09-18 Tonix Pharma Holdings Limited Eutectic formulations of amitriptyline hydrochloride and mannitol
CN105960397B (en) 2014-02-05 2020-09-04 默沙东公司 Tablet formulations of CGRP-active compounds
AU2015317336B2 (en) * 2014-09-18 2021-01-21 Tonix Pharma Holdings Limited Eutectic formulations of Cyclobenzaprine hydrochloride
CN111447971A (en) * 2017-12-11 2020-07-24 通尼克斯制药控股有限公司 Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
EP3840738A1 (en) * 2018-08-20 2021-06-30 Tonix Pharma Holdings Limited Methods of treating acute stress disorder and posttraumatic stress disorder
NL2023661B1 (en) 2019-08-19 2021-04-21 Seranovo Holding B V Pharmaceutical Eutectic Salt Formulation
JP7088153B2 (en) * 2019-09-19 2022-06-21 カシオ計算機株式会社 CAP (Periodic EEG Activity) Detection Device, CAP (Periodic EEG Activity) Detection Method and Program
EP4132648A1 (en) * 2020-04-08 2023-02-15 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for sexual dysfunction
CN116887830A (en) * 2020-11-20 2023-10-13 通尼克斯医药控股公司 Cyclobenzaprine treatment of alcohol use disorders
EP4255407A1 (en) 2020-12-07 2023-10-11 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for fibromyalgia
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2022170107A2 (en) 2021-02-04 2022-08-11 Tonix Pharmaceuticals Holding Corp. An improved method of assessing clinical response in the treatment of ptsd symptoms
CN113116843A (en) * 2021-05-11 2021-07-16 福建海西新药创制有限公司 Pharmaceutical composition containing valsartan and preparation method thereof
WO2023059728A1 (en) 2021-10-06 2023-04-13 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients
US20230414536A1 (en) 2022-06-21 2023-12-28 Tonix Pharmaceuticals Holding Corp. CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF (SARS)-CoV-2 INFECTION (PASC)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077297A1 (en) * 1999-02-26 2003-04-24 Feng-Jing Chen Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20050181041A1 (en) * 2003-12-09 2005-08-18 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
US20070141144A1 (en) * 2004-05-28 2007-06-21 Roberts Michael S Oral delivery system
US20080146672A1 (en) * 2006-12-08 2008-06-19 Denton Marcia Marye Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue
US20090098200A1 (en) * 2007-09-25 2009-04-16 Solubest Ltd. Compositions comprising lipophilic active compounds and method for their preparation
US20100021507A1 (en) * 2007-08-30 2010-01-28 Bunick Frank J Method and Composition for Making an Orally Disintegrating Dosage Form

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968507A (en) 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
IL72684A (en) 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
JP2551754B2 (en) * 1986-04-17 1996-11-06 内橋エステック 株式会社 Pellet type temperature fuse
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
FR2635461B1 (en) 1988-08-18 1992-01-17 Adir USE OF TRICYCLIC DERIVATIVES FOR OBTAINING MEDICINES FOR TREATING STRESS
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
CN1245156C (en) 1993-02-22 2006-03-15 美国生物科学有限公司 Methods for in vivo delivery of biologics and compositions useful therefor
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
DE4439858A1 (en) * 1994-11-08 1996-05-09 Merck Patent Gmbh By co-spray drying available polyol composition
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US6649186B1 (en) * 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO1999018937A1 (en) 1997-10-16 1999-04-22 Merck & Co., Inc. New cyclobenzaprine composition
PT1077683E (en) 1998-05-14 2003-04-30 Alza Corp ANTI-DEPRESSIVE THERAPY
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
ES2245944T3 (en) 1999-08-13 2006-02-01 Vela Pharmaceuticals Inc USE OF COMPOSITIONS TO TREAT OR PREVENT SLEEP ALTERATIONS USING VERY LOW DOSE CYCLLOBENZAPRINE DOSE.
US6358944B1 (en) 1999-08-13 2002-03-19 Vela Pharmaceuticals, Inc. Methods and compositions for treating generalized anxiety disorder
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
WO2001089476A1 (en) 2000-05-19 2001-11-29 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
ATE427745T1 (en) 2001-11-05 2009-04-15 Krele Pharmaceuticals Llc COMPOSITIONS AND METHODS FOR INCREASE COMPLIANCE WITH THERAPIES USING ALDEHYDE DEHYDROGENASE INHIBITORS AND FOR TREATING ALCOHOLSM
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7105486B2 (en) 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
JP4288263B2 (en) 2002-10-25 2009-07-01 コレジウム ファーマシューティカル， インク． Stereoisomers of p-hydroxy-milnacipran and methods of use thereof
HUE040046T2 (en) 2002-12-09 2019-02-28 Abraxis Bioscience Llc Compositions and methods of delivery of pharmacological agents
US20050059656A1 (en) 2003-04-07 2005-03-17 Cornell Research Foundation, Inc. Compositions and methods for protecting against mitochondria component-mediated pathology
CA2527646C (en) 2003-05-29 2011-08-23 New River Pharmaceuticals Inc. Abuse resistant amphetamine compounds
CA2543710A1 (en) 2003-11-03 2005-05-12 Warner-Lambert Company Llc Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
US20050143350A1 (en) 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
KR20150038745A (en) 2004-02-17 2015-04-08 트랜스셉트 파마슈티칼스, 인코포레이티드 Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
TWI377913B (en) 2005-01-24 2012-12-01 Food Science Co Ltd B Eutectic crystalline sugar alcohol and manufacturing method thereof
US7532935B2 (en) 2005-07-29 2009-05-12 Cyberonics, Inc. Selective neurostimulation for treating mood disorders
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
NZ581707A (en) 2007-05-07 2011-05-27 Chelsea Therapeutics Inc Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
WO2009002770A1 (en) 2007-06-22 2008-12-31 Merck & Co., Inc. 6.5-pyrrolopiperidine tachykinin receptor antagonists
CN101951912A (en) 2007-07-23 2011-01-19 辛诺西亚治疗公司 Treatment of post-traumatic stress disorder
WO2009058950A2 (en) * 2007-10-30 2009-05-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
US20090148532A1 (en) 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
CA3066426A1 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US8586103B2 (en) 2008-02-08 2013-11-19 Foresee Pharmaceuticals, Llc Non-polymeric compositions for controlled drug delivery
US9314469B2 (en) 2008-05-05 2016-04-19 Tonix Pharma Holdings Limited Method for treating neurocognitive dysfunction
JP5380909B2 (en) 2008-05-30 2014-01-08 株式会社ブリヂストン Mold and molding method of resin foam molding
US20100266682A1 (en) 2008-12-10 2010-10-21 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
US20100247586A1 (en) 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
EP2233134A1 (en) 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties
US8807979B2 (en) * 2009-09-24 2014-08-19 Mcneil-Ppc, Inc. Machine for the manufacture of dosage forms utilizing radiofrequency energy
WO2011062614A1 (en) 2009-11-20 2011-05-26 Tonix Pharmaceuticals, Inc. Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
DK2611440T3 (en) 2010-09-01 2017-05-15 Tonix Pharmaceuticals Inc Treatment for cocaine addiction
US20120232159A1 (en) 2011-03-07 2012-09-13 Tonix Pharmaceuticals, Inc. Methods and Compositions for Treating Depression using Cyclobenzaprine
ITMI20110558A1 (en) 2011-04-06 2012-10-07 Campiglio Consulting Srl PHARMACEUTICAL COMPOSITION CONTAINING CYCLOBENZAPRINE SUITABLE FOR ENDONASAL ADMINISTRATION
PT2739266T (en) 2011-08-04 2016-10-04 Omeros Corp Stable anti-inflammatory solutions for injection
JP6259452B2 (en) 2012-06-15 2018-01-10 トニックス ファーマシューティカルズ， インコーポレイテッド Compositions and methods for transmucosal absorption
CA3119755A1 (en) 2013-03-15 2014-09-18 Tonix Pharma Holdings Limited Eutectic formulations of amitriptyline hydrochloride and mannitol
AU2015317336B2 (en) * 2014-09-18 2021-01-21 Tonix Pharma Holdings Limited Eutectic formulations of Cyclobenzaprine hydrochloride
EP3840738A1 (en) 2018-08-20 2021-06-30 Tonix Pharma Holdings Limited Methods of treating acute stress disorder and posttraumatic stress disorder

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077297A1 (en) * 1999-02-26 2003-04-24 Feng-Jing Chen Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20050181041A1 (en) * 2003-12-09 2005-08-18 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
US20070141144A1 (en) * 2004-05-28 2007-06-21 Roberts Michael S Oral delivery system
US20080146672A1 (en) * 2006-12-08 2008-06-19 Denton Marcia Marye Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue
US20100021507A1 (en) * 2007-08-30 2010-01-28 Bunick Frank J Method and Composition for Making an Orally Disintegrating Dosage Form
US20090098200A1 (en) * 2007-09-25 2009-04-16 Solubest Ltd. Compositions comprising lipophilic active compounds and method for their preparation

Also Published As

Publication number Publication date
EP2968992A4 (en) 2016-09-07
DK2968992T3 (en) 2020-02-03
CN105142730B (en) 2019-04-16
LT2968992T (en) 2020-03-25
AU2014233277A1 (en) 2015-10-29
CN105142730A (en) 2015-12-09
US9636408B2 (en) 2017-05-02
US20140336264A1 (en) 2014-11-13
TW201519889A (en) 2015-06-01
SA515361124B1 (en) 2018-09-13
US20190282517A1 (en) 2019-09-19
JP2016515528A (en) 2016-05-30
US10864175B2 (en) 2020-12-15
EP2968992A2 (en) 2016-01-20
TWI740136B (en) 2021-09-21
PL2968992T3 (en) 2020-06-01
CA2904812A1 (en) 2014-09-18
EP2968992B1 (en) 2019-12-11
PT2968992T (en) 2020-02-18
CN110152005B (en) 2023-08-04
WO2014145156A2 (en) 2014-09-18
US11839594B2 (en) 2023-12-12
BR112015022095A8 (en) 2019-11-26
JP6310542B2 (en) 2018-04-11
JP2019196407A (en) 2019-11-14
CA3119755A1 (en) 2014-09-18
SG10201707528WA (en) 2017-10-30
US20160030576A1 (en) 2016-02-04
SG11201507124XA (en) 2015-10-29
AU2014233277B2 (en) 2019-04-04
EP2968992B8 (en) 2020-01-15
CA2904812C (en) 2021-07-20
TW201936180A (en) 2019-09-16
US20180344668A1 (en) 2018-12-06
JP2023181495A (en) 2023-12-21
HK1218727A1 (en) 2017-03-10
US20190022031A1 (en) 2019-01-24
IL241353B (en) 2019-10-31
US9956188B2 (en) 2018-05-01
US20170239195A1 (en) 2017-08-24
BR112015022095A2 (en) 2017-07-18
MX370021B (en) 2019-11-28
EP3650081B1 (en) 2024-02-14
CY1122740T1 (en) 2021-03-12
TWI661825B (en) 2019-06-11
EP3650081A1 (en) 2020-05-13
HUE047547T2 (en) 2020-04-28
US11737991B2 (en) 2023-08-29
US20210038538A1 (en) 2021-02-11
ES2769879T3 (en) 2020-06-29
SI2968992T1 (en) 2020-04-30
IL241353A0 (en) 2015-11-30
CN110152005A (en) 2019-08-23
JP2021143208A (en) 2021-09-24
MX2015012622A (en) 2016-05-31
MY196014A (en) 2023-03-06
RS60015B1 (en) 2020-04-30
US10864176B2 (en) 2020-12-15
US10322094B2 (en) 2019-06-18
US20210093585A1 (en) 2021-04-01
US10117936B2 (en) 2018-11-06
JP2018087231A (en) 2018-06-07
HRP20200055T1 (en) 2020-04-03
NZ631152A (en) 2017-05-26
US10736859B2 (en) 2020-08-11
US20190022030A1 (en) 2019-01-24
MX2019014200A (en) 2020-01-27

Similar Documents

Publication Publication Date Title
WO2014145156A3 (en) Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
HK1219432A1 (en) Pharmaceutical composition having pyrimidine compound as active ingredient
MX2017003644A (en) Eutectic formulations of cyclobenzaprine hydrochloride.
BR112015003259A2 (en) compound, pharmaceutical composition, and vaccine composition.
SG11201509436TA (en) Pharmaceutical composition, preparation and uses thereof
EA201491517A1 (en) N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DIHYDROXI-1-METHYL-2-OXO-3-HINOLINKARBOXAMID, ITS PREPARATION AND APPLICATION
DK3411008T3 (en) Compositions comprising active sunscreens with polyhydroxyfullerene
IL249010A0 (en) Pharmaceutical composition comprising pyrazine carboxamide compound as active ingredient
HK1248225A1 (en) Pharmaceutical compositions of a dihydropyrazino-pyrazine compound, a solid form thereof and uses of the same
WO2014105777A8 (en) Cobicostat dichlohydrate salt
BR112014032501A2 (en) compound and pharmaceutical composition.
IL262929A (en) Composition, and application and pharmaceutical preparation thereof
RS62793B1 (en) Anticancer heterobasidion annosum extract, compositions and uses thereof
DK3324736T3 (en) New spot-on active ingredient formulation
WO2015136372A3 (en) Eutectic isometheptene mucate
SG11201700122TA (en) Pharmaceutical compound comprising 13 glycerides, formulation and application thereof
EP3530652A4 (en) Modified phenylphthalimide and pharmaceutical composition having same as active ingredient
NZ747040A (en) Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
IL242563B (en) Pharmaceutical composition, preparation and uses thereof
TH148806B (en) Improved stability of the pharmaceutical formulation.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480024011.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14762323

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2904812

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 241353

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2016503239

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/012622

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 14776624

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: IDP00201506570

Country of ref document: ID

WWE Wipo information: entry into national phase

Ref document number: 2014762323

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014233277

Country of ref document: AU

Date of ref document: 20140314

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14762323

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015022095

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112015022095

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150909